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Abstract: Dopamine D2 receptors (D2R) are known to form transient homodimer complexes, of
which the increased formation has already been associated with development of schizophrenia.
Pharmacological targeting and modulation of the equilibrium of these receptor homodimers might
lead to a better understanding of the critical role played by these complexes in physiological
and pathological conditions. Whereas agonist addition has shown to prolong the D2R dimer
lifetime and increase the level of dimer formation, the possible influence of D2R antagonists on
dimerization has remained rather unexplored. Here, using a live-cell reporter assay based on
the functional complementation of a split Nanoluciferase, a panel of six D2R antagonists were
screened for their ability to modulate the level of D2LR dimer formation. Incubation with the
D2R antagonist spiperone decreased the level of D2LR dimer formation significantly by 40–60% in
real-time and after long-term (≥16 h) incubations. The fact that dimer formation of the well-studied
A2a–D2LR dimer was not altered following incubation with spiperone supports the specificity of
this observation. Other D2R antagonists, such as clozapine, risperidone, and droperidol did not
significantly evoke this dissociation event. Furthermore, molecular modeling reveals that spiperone
presents specific Tyr1995.48 and Phe3906.52 conformations, compared to clozapine, which may
determine D2R homodimerization.
Keywords: G protein-coupled receptor (GPCR); dimerization; oligomerization; protein complementation
assay; NanoLuc binary technology (NanoBiT); dopamine D2 receptor
1. Introduction
Dopamine receptors belong to the class A sub-family of G protein-coupled receptors (GPCRs).
Five dopamine receptors have been identified in mammals and are classified in the D1-like family, with
the D1 and D5 subtypes, and the D2-like family, with the D2, D3, and D4 subtypes [1]. They are key
players in the coordination of motor control, cognitive function, memory, and reward [2,3]. A growing
body of evidence indicates that the signaling function of many GPCRs is diversified and fine-tuned by
interaction with other GPCRs [4]. Dimerization of GPCRs has been demonstrated both in vitro and
in vivo, whereby association may take place with the same GPCR (homo-oligomerization) or with
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different GPCRs (hetero-oligomerization) [5]. Dimerization phenomena have been documented for all
five dopamine receptor subtypes [6–9]. Towards this end, extensive work has been directed towards
the dopamine D2 sub-type receptor (D2R). This receptor plays an important role in the physiological
actions of the neurotransmitter dopamine, and it is a target for drugs used to treat schizophrenia and
Parkinson’s disease, depression, attention deficit hyperactivity, stress, nausea, and vomiting [10–16].
The D2R exists in two isoforms, D2,short (D2SR) and D2,long (D2LR), generated by alternative
splicing [17,18]. The difference is a 29-amino acid fragment insertion in the third intracellular loop
(ICL3) of the D2LR. Although a large number of dimer complexes of D2R with other GPCRs have been
extensively documented ((A2a-D2R; [19,20])(β2-D2R; [21])(CB1-D2R; [22,23])), this receptor can form
homodimer complexes as well. It was first reported in 1996 by Ng et al. [24] that D2LR forms homodimers,
as observed by co-immunoprecipitation (co-IP). Further evidence for homodimerization of both isoforms
has been provided by studies using a wide variety of biochemical techniques such as co-IP, ligand
binding [25], fluorescence resonance energy transfer (FRET) [26], bioluminescence resonance energy
transfer (BRET) [27], single-molecule tracking [28], and protein–protein docking [29,30]. Furthermore,
it has been suggested that the extent of dimerization is subtype-selective (D2LR > D2SR), suggesting a
possible role for the 29-amino-acid fragment in ICL3 [31].
In order to better understand the crosstalk between dopamine receptors, the interface(s) should
be considered from a molecular point of view. Different transmembrane (TM) regions of the
D2R have been reported to be involved in the D2R homodimer interface. Incubation of D2R
homodimers with peptides derived from the putative TM6 regions of the D2R resulted in dissociation
of the dimer to the monomers [24,32]. On the other hand, successive deletion of TM domains of
the D2R and cysteine cross-linking studies revealed that the most critical areas involved in the
intermolecular hydrophobic interactions for dimerization resided in TM4 [33,34]. In addition, the
TM4–TM5–TM4–TM5 and TM5–TM6–TM5–TM6 interfaces have been widely described to be involved
in D2R hetero-oligomerization with other class A GPCRs [35–40]. In 2014, Guitart et al. [41] reported
that dopamine D1 receptor (D1R) TM5- or TM6-derived single peptides were able to reduce D1R
homodimerization. Likewise, a potential TM5–TM6–TM5–TM6 interface could be envisaged in the D2R
homodimer. Collectively, these reported features support the hypothesis of multiple oligomerization
interfaces [42], wherein GPCRs undergo multiple cycles of monomer and dimer formation with
different interfaces. These interfaces can differ between homo- and heterodimerization processes
of GPCRs. This concept of oligomerization of the D2R has also been confirmed by combined FRET
and BRET assays, wherein at least four dopamine D2R monomers are closely located at the plasma
membrane, suggesting higher-order oligomer formation [43,44].
Although it was first postulated that D2Rs form constitutive dimers or higher-order oligomers [34],
increasing evidence supports the dynamic interconversion between monomers and dimers, suggesting
transient dimer formation [28,42]. Recently, a lifetime of 0.5 s was determined for SNAP-tagged D2LR
dimers using single-molecule sensitive total internal reflection fluorescence (TIRF) microscopy [31].
Whereas Tabor et al. detected transient D2R homodimer formation at 24 ◦C, Kasai et al. (2017) [28]
performed single-molecule imaging at the physiological temperature of 37 ◦C, resulting in transient
D2R dimer formation with a lifetime of 68 ms. Similar findings for temperature-dependent lifetimes of
homodimer formation were also observed for other class A GPCRs [45–47].
The emerging evidence on transient dynamics of class A GPCR dimers, characterized by
fast association and dissociation events, adds to the understanding of the complexity of receptor
dimerization. Considering the dynamics and transient nature of D2R dimers, one might anticipate
a functional relevance for alterations in the level of D2R dimerization. Indeed, an increase in D2R
homodimer formation has been correlated with the pathophysiology of schizophrenia [48]. Therefore,
targeting these D2R dimers might offer new information about the pathophysiology of diseases related
to this GPCR dimer, potentially opening new therapeutic avenues.
Within the concept of altering the level of dimerization or even oligomerization provoked
by ligands, different screening methods have been implemented. For example, FRET has been
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used to monitor dose-dependent increases in the level of D2SR oligomerization by the agonist
(−)-norpropylapomorphine [26]. Tabor et al. (2016) [31] used TIRF microscopy to investigate the effect
of D2R agonists dopamine and quinpirole on the spatial and temporal organization of D2R dimer
formation. These authors found that agonist stimulation at high concentrations (15 µM) seemed to
prolong the lifetime of the D2R homodimer by a factor of ~1.5, whereas the neutral antagonist UH-232
(0.1 µM) did not alter the lifetime of the dimer.
To our knowledge, research on monovalent antagonist-mediated modulation of D2R dimerization
is rather limited. The neutral UH-232 and 1,4-DAP have been tested, but no effect was observed [31].
In the present study, the modulating capacity of several clinically used D2R antagonists/inverse
agonists on the level of D2R homodimerization or higher-order oligomerization was evaluated using
complementation-based NanoLuciferase® Binary Technology (NanoBiT®). In addition, an atomistic
computational study of D2R conformational changes induced by specific D2R antagonists/inverse
agonists and its relevance on D2R homodimerization has been performed using microsecond-length
unbiased molecular dynamics (MDs) simulations.
2. Results
2.1. Pharmacological Properties of the D2LR Fusion Proteins
For the development of a complementation-based GPCR dimer targeting strategy, the D2LR was
C-terminally fused to the small 1 kDa subunit (Small BiT, SmBiT) and to the large 18 kDa subunit
(Large BiT, LgBiT) of NanoLuciferase. Upon interaction with D2LR monomers, the NanoLuciferase
subunits were brought into close proximity and re-assembled spontaneously into a functional
protein. To ensure that these modified D2LR fusion constructs retained functionality, we performed a
G-protein coupling assay. We therefore cloned the mini-Gαi protein, corresponding to the engineered
GTPase domain of the Gαi subunit fusion proteins, into the NanoBiT vectors with either LgBiT
or SmBiT at their N-terminus. These mini-Gαi fusion proteins were transiently co-expressed with
the corresponding (complementary) D2LR fusion constructs in HEK293T cells that were stimulated
with the dopamine D2R agonist quinpirole (0.01 nM–10 µM). N-terminally tagged mini-Gαi proteins
showed a concentration-dependent recruitment to the D2LR–SmBiT and D2LR–LgBiT fusion constructs
(Figure 1). This demonstrated (i) that both receptor fusion constructs were expressed at the cell surface,
(ii) that both receptor fusion constructs were responsive to ligand-induced activation, and (iii) that
both receptor fusion constructs could still undergo a conformational change upon receptor modulation.
Interestingly, the different construct combinations resulted in a dissimilar output in terms of sensitivity
and signal-to-noise ratio, as published previously for the G-protein coupling assay with D2R [49].
Accordingly, pEC50 values for D2LR–LgBiT and SmBiT–mini-Gαi in comparison with D2LR–SmBiT and
LgBiT–mini-Gαi deviated substantially (pEC50: 6.62 ± 0.02 and 7.65 ± 0.05, respectively). Although
both D2LR fusion proteins can recruit mini-Gαi in a concentration-dependent manner and, thus,
are functional, these observations further underscored the importance of testing several construct
combinations when implementing systems like this for deducing EC50 values.
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Figure 1. Real-time monitoring of mini-Gαi protein recruitment to the D2LR by the NanoLuciferase
Binary Technology (NanoBiT) assay. Transient overexpression of fusion constructs of the LgBiT and
SmBiT of NanoLuciferase C-terminal to D2LR and N-terminal to the mini-Gai-protein was achieved in
HEK293T cells. Luminescence was monitored for 2 h. Concentration-response curves were generated
by the addition of quinpirole (0.01 nM–10 µM), and the corresponding AUCs (four independent
experiments, in triplicate) normalized and plotted to the logarithmic concentration of quinpirole
(n = 12, ±SEM).
2.2. Targeting the Dopamine D2LR Homodimer using the NanoBiT Assay
To target D2LR homodimers in their native cell environment, the D2LR–LgBiT and D2LR–SmBiT
fusion constructs were transiently transfected in HEK293T cells. This cell line was selected because of
its high transient transfection efficiency as well as its rapid growth characteristics. More importantly,
within a comparative study of four different cell lines frequently used for GPCR research, the HEK293
cell line showed the lowest expression (both amount and type) of GPCRs and could thereby serve as
an appropriate cell model into which gene constructs of interest can be introduced [50]. Within this
experimental setup, a clear luminescent signal was obtained when the D2LR–LgBiT and D2LR–SmBiT
were co-expressed, indicating interaction of both receptors (Figure 2A). As negative controls, expression
of the D2LR–LgBiT or D2LR–SmBiT separately only generated a signal that could be considered as
background (i.e., seven- to ten-fold lower compared to the signal observed for the D2LR homodimer),
as expected. As an additional negative control, we co-expressed the HaloTag–SmBiT construct, a
fusion protein that is diffusively expressed throughout the cell. Again, a response not significantly
(p > 0.05) different from background was detected (i.e., a five-fold lower signal was observed as
compared to the signal provoked by the D2LR homodimer). Furthermore, from a screening of multiple
GPCRs, the cannabinoid receptor 2 (CB2) was selected as a non-interacting partner for D2LR since no
significant (p > 0.05) increase in luminescent signal was observed for the CB2–D2LR combination in
direct comparison to the negative control D2LR–LgBiT with HaloTag–SmBiT. To our knowledge, no
dimer formation of CB2 with D2R has been reported, in contrast to the CB1 for which dimerization with
the D2R has been described [51]. Functionality of the CB2 constructs was demonstrated elsewhere [52].
In addition, the signal obtained for CB2–D2LR was significantly (four-fold) lower compared to
that obtained for the D2LR–D2LR combination. The aforementioned results supported the utility
of a NanoLuciferase complementation assay to differentiate between interacting (D2LR–D2LR) and
non-interacting GPCRs (CB2–D2LR), when compared to background.
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2.3. Antagonist-Dependent Modulation of the Level of D2LR Homodimer Formation
2.3.1. Short-Term Effects
The short-term effect of the D2R antagonists haloperidol, spiperone, and clozapine on the
level of dimerization was first evaluated on adherent HEK293T cells transiently transfected with
D2LR–LgBiT and D2LR–SmBiT. Observed luminescent signals were corrected for solvent control,
and the normalized relative luminescence units (RLU) were plotted against time (Figure 2B). A
steeper drop in luminescent signal was observed when incubated for 1 h with spiperone (10 µM)
compared to haloperidol or clozapine (Figure 2B). Although one should recognize the possible decay
of the NanoGlo substrate, which was considered similar in all conditions, nevertheless, a clear
difference in decrease in luminescent signal was observed when incubated with different antagonists
(spiperone > haloperidol > clozapine).
2.3.2. Long-Term Effects
For longer incubation time points, the capability of modulating the level of dimerization of the D2R
antagonists haloperidol, spiperone, and clozapine was validated on cells in suspension. To circumvent
fluctuations in the observed effect due to transfection variability, the obtained luminescent signal was
normalized to the fluorescent signal obtained from the same amount of co-transfected Venus protein
in all conditions. The normalized luminescent signal was measured after 10 min (Supplementary
Materials, Figure S1), 30 min (Supplementary Materials, Figure S2), 4 h and 16 h of incubation with the
D2R antagonists (Figure 2C,D). The effect of spiperone on the D2LR homodimer could be observed
after 30 min and was sustained for up to 16 h of incubation. Spiperone reduced the level of D2LR
dimerization by 40%–60%, depending on the time interval of incubation. This decrease in D2LR
dimerization levels was only provoked upon incubation with a spiperone concentration ≥10 µM.
2.3.3. Screening of a Broader Panel of D2R ligands
To investigate a possible class-dependent effect of D2R antagonists on the D2LR dimer, a broader
panel of D2R ligands, including droperidol, spiperone, clozapine, olanzapine, risperidone, quinpirole,
and haloperidol, was screened for their capacity to modulate the level of D2LR homodimer formation
following long-term incubation (16 h). Of these, droperidol, clozapine, risperidone, and the D2R
agonist quinpirole did not significantly (p > 0.05) modify the luminescent signal provoked by the dimer
(Figure 3A). Haloperidol only slightly decreased the level of dimer formation (±30%). On the other
hand, the D2R antagonist olanzapine clearly enhanced the luminescent signal by 45%. Finally again,
the most significant effect was seen upon incubation with spiperone, with a clear reduction of 40–60%.
2.4. Validation of the Spiperone-Modulating Capacity on the D2LR Homodimer
Several experimental setups were implemented to validate the modulating capacity of spiperone
on the D2LR dimer by investigating: (i) possible artifacts, (ii) expression levels of the D2LR, and (iii) the
specificity of the effect of spiperone on the D2LR dimer.
Firstly, to exclude that the observed effect was a result of possible artifacts such as toxicity, the
possible influence of spiperone on the activity of native NanoLuciferase, transiently expressed in
HEK293T cells, was investigated. Cells expressing the native luminescent enzyme were incubated for
different time points with 10 µM of the antagonists. No impact on luciferase activity was observed
(Supplementary Materials, Figure S3).
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Secondly, to rule out a possible role for spiperone on the expression level of the D2LR, the
receptor was fused to yellow fluorescent protein (YFP) and HEK293T cells transiently transfected
with the fusion construct, and they were incubated with 10 µM of the D2R antagonists haloperidol,
clozapine, and spiperone (Figure 3B). Incubation with these D2R antagonists did not cause any
significant alteration in the level of fluorescent signal after 16 h of incubation. Similarly, a western
blot experiment under reducing conditions was conducted to analyze the expression of the fusion
proteins D2LR–SmBiT and D2LR–LgBiT in both cells that had been and had not been incubated with
the antagonists (Figure 3C). The aim of this experiment was merely to evaluate whether there was an
impact on D2LR expression. After normalization to tubulin as a housekeeping protein, a 14% decrease
of D2LR fusion protein expression was observed in cells treated with spiperone, compared to the
solvent-treated control. Under these (reducing) conditions, no clear bands of D2LR dimers or higher
oligomers could be observed, which might be explained by the fact that lower densities of receptors
in the plasma membrane could conceivably reduce the proportion of receptors forming dimers, as
reported before [53].
Finally, the specificity of the effect of spiperone on the D2LR homodimer was evaluated by
examining its effect on another well-studied GPCR dimer, namely the adenosine A2a receptor–D2R
dimer [19,20,54]. We therefore co-expressed A2a–LgBiT and D2LR–SmBiT in HEK293T cells that were
treated with 10 µM spiperone for 16 h (Figure 3D). No significant effect (p > 0.05) was observed on the
level of A2a–D2LR dimer formation, lending further support to the specificity of the effect of spiperone
on the D2LR homodimer.
2.5. Spiperone and Clozapine Achieve Stable Binding Poses in D2R during Molecular Dynamics Simulations
In order to comprehend how spiperone might reduce D2R homodimerization relative to clozapine
at the molecular level, we first docked each ligand into the crystal structure of D2R (PDB id: 6CM4) [55]
and then performed unbiased molecular dynamics (MDs) simulations to allow for ligand-induced
conformational changes to occur in the monomeric receptor. During respective time periods of
3 µs, both spiperone and clozapine achieved stable binding poses (Figure 4A) despite some initial
conformational changes in both ligands, as might be expected (Supplementary Materials, Figure S4A).
Specifically, clozapine and spiperone achieved stable bound conformations from 0.4 and 1.8 µs onwards,
respectively, where root mean square deviation (RMSD) from their final conformations remained <3.0 Å
(average of 1.5 Å ± 0.5 S.D. for clozapine and 1.9 Å ± 1.0 S.D. for spiperone). The relative higher
conformational fluctuation observed with spiperone can be attributed to its greater flexibility, mainly
due to its central alkyl chain. Despite clozapine and spiperone reaching stable binding poses at
different times, in both cases the D2R monomer presented little conformational change of its backbone,
with final values of 2.5 Å and 2.2 Å, respectively (Supplementary Materials, Figure S4B). In the
original crystal structure, residues in close contact with co-crystallized risperidone [54] (<3.5 Å) were
located on extracellular loop 1 (ECL1), TM3, TM5, and TM6 (Table 1 and Supplementary Materials,
Figure S5). In terms of the protein–ligand interactions in common between risperidone, spiperone,
and clozapine, the most prominent was an electrostatic interaction between the protonated ligand
amine group and Asp1143.32 (superscript numbers refer to the Ballesteros and Weinstein generic
numbering scheme [56], which includes relative TM helix location) on TM3, which was maintained
over respective MD simulations. Other common interactions, which occurred once each ligand found
its stable binding pose, included contacts with residues on TM3, TM5, and extracellular loop 2 (ECL2):
Val1153.33, Ile184ECL2, and Ser1935.42 (Figure 4A and Table 1). However, clozapine established several
distinct contacts with residues on TM5 and TM6. On the other hand, spiperone was frequently in
contact with residues on TM2 and TM3 (Table 1). These different residues in contact with clozapine
and spiperone demonstrated that their binding poses were quite different (Figure 4A and Table 1).
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Figure 4. D2R monomer and homodimer complexes. Transmembrane helices are labeled as TM. (A) 2D
and 3D (top and bottom, respectively) stable binding poses of residues (abbreviated following three
letter or single letter code, respectively) in close contact during molecular dynamics (MD) simulation
(<3.5 Å) with clozapine and spiperone (dark red and purple, respectively) bound to respective D2R
monomer (left and right, colored in orange and blue, respectively). (B) Trans and cis conformations
of Tyr1995.48 and Phe3906.52 χ1 dihedral angles selected by bound clozapine or spiperone (dark
red and purple respectively) bound to D2R monomer (left and right, colored in orange and blue,
respectively). (C) From left to right, lateral and intracellular views of TM5–TM6–TM5–TM6 D2R
homodimer model interface, which generates aromatic interactions between Tyr1995.48 and Phe3906.52
of both D2R protomers during MD simulation (colored in purple or green, respectively).
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Table 1. Protein–ligand interactions (<3.5 Å) of co-crystallized risperidone, and stably bound clozapine
and spiperone during MD simulations. (i) Common residues in contact between all ligands; (ii) common
residues in contact between risperidone and clozapine; (iii) common residues in contact between
risperidone and spiperone; (iv) common residues in contact between clozapine and spiperone.
Ligand Unique Interactions Common Interactions
Risperidone Trp100ECL1 Asp1143.32 (I)
Ser1975.48 Cys1183.36 (III)
Phe3826.44 Ile1223.40 (III)
Tyr4167.43 Trp3866.48 (II)
Phe3896.51 (II)
Clozapine Phe1895.38 Asp1143.32 (I)
Ser1935.42 Val1153.33 (IV)
Phe1985.47 Ile184ECL2 (IV)
Phe3906.52 Ser1935.42 (IV)
His3936.55 Trp3866.48 (II)
Phe3896.51 (II)
Spiperone Val912.61 Asp1143.32 (I)
Phe1103.28 Val1153.33 (IV)
Cys1183.36 (III)
Ile1223.40 (III)
Ile184ECL2 (IV)
Ser1935.42 (IV)
2.6. Spiperone and Clozapine Select for Different Sidechain Conformations in D2R TM5 and TM6
To ascertain the most important conformational changes selected by the stable binding poses
of clozapine and spiperone in D2R, we carried out residue-level analyses of the monomeric MD
simulations. No significant conformational differences between systems were observed in any
residues located on TM helices, except for TM5 and TM6. Specifically, neighboring residues Tyr1995.48
and Phe3906.52 showed different χ1 dihedral angle conformations with different bound antagonists.
In general, for these two aromatic residues, two different pseudo-stable conformations can be observed
in our MD simulations, a cis and a trans χ1 dihedral angle of 300◦ and 180◦, respectively (Figure 4B).
The D2R crystal structure presented cis conformations for both Tyr1995.48 and Phe3906.52, which
underwent conformational changes to trans more frequently when clozapine was bound than with
spiperone (Supplementary Materials, Figure S6). Specifically, considering only time periods where
clozapine and spiperone presented stable binding poses (from 0.4 and 1.8 µs onwards, respectively)
clozapine preferentially selected for Tyr1995.48 and Phe3906.52 χ1 trans conformations 99% of the
time. This “double” χ1 trans conformation led to an outward orientation (towards the membrane)
for Tyr1995.48 and Phe3906.52, which potentially may encourage protein–protein interactions through
the formation of aromatic contacts, which are known to be important (Figure 4B) [57]. Conversely,
spiperone induced rapid fluctuations between χ1 cis and trans conformations of Tyr1995.48, with the
cis selected 25% of the time, whereas the cis conformation of Phe3906.52 was exclusively maintained.
The χ1 cis conformation of Tyr1995.48 and Phe3906.52 oriented them in a more inward position, away
from the membrane, which may conceivably discourage protein–protein interactions (Figure 4B).
2.7. Aromatic Interactions Stabilize D2R Homodimer Model Interface during MD Simulation
In order to probe how a D2R homodimer might be affected by sidechain conformational changes
in TM5 and TM6, a D2R homodimer without bound antagonist was modeled from the original
crystal structure with a TM5–TM6–TM5–TM6 interface (in line with experimental evidence by
Pulido, 2018 [32]) by protein–protein docking. This resulted in a D2R homodimer with a highly
favorable interface docking score of −9.7 (on a scale of 0 to −10, where lower than −5.0 was
considered satisfactory ([58]); see Methods). This model was subjected to an MD simulation of
3 µs to investigate homodimer physical stability and receptor conformational changes in individual
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protomers (Figure 4C). During this MD simulation, the TM5–TM6–TM5–TM6 interface remained
intact, according to a consistently close interaction distance (Supplementary Materials, Figure S4C)
between TM5/TM6 helices of each protomer. In the process, participating helices experienced a
moderate backbone conformational change of 3.2 Å in order to enhance mutual binding, obtaining
an average interaction energy of −11.7 kcal/mol (±3.2 S.D.) between protomers (Supplementary
Materials, Figure S4B,D). Furthermore, from an analysis of individual protomers in the homodimer, it
can be observed that one protomer underwent slightly more backbone conformational changes than the
others during the second half of MD (average RMSDs of 2.9 Å and 2.3 Å, respectively (Supplementary
Materials, Figure S4B)). To ascertain the relevance of interactions involved in the TM5–TM6–TM5–TM6
homodimer interface, we performed a conformational and energetic analysis of specific residues on
TM5 and TM6. Interestingly, the D2R protomer whose backbone remained relatively unchanged
rapidly selected for the cis to trans conformational change of Tyr1995.48 and Phe3906.52 χ1 dihedral
angles (Figure 4C), which occurred at 94% and 90% of the total MD simulation time, respectively
(Supplementary Materials, Figure S6). In addition, a rapid cis to trans conformational change of
Phe3906.52 χ1 dihedral angle was observed in the other protomer (occurring at 93% of total time).
However, in this second protomer, Tyr1995.48 presented no significant conformational change and
remained in the cis conformation (Supplementary Materials, Figure S6). As shown in Figure 4C, the
outward conformations achieved by Tyr1995.48 and Phe3906.52 in the homodimer enabled an aromatic
interaction network to form, as well as transient H-bond formation between Tyr1995.48 sidechains
of both protomers (H-bond occupancy of 4%). As a result, the average minimum distance between
Tyr1995.48/Phe3906.52 residues of each protomer was 5.5 Å (±1.5 S.D.) (Supplementary Materials,
Figure S4C). From an energetic point of view, alanine scanning of Tyr1995.48 and Phe3906.52 confirmed
the relevance of these residues in the D2R homodimer interface. Removal of these aromatic interactions
(by alanine mutation) resulted in a less favorable average interface energy of−8.6 kcal/mol (±2.8 S.D.),
which suggested this aromatic interaction network contributed an average of −3.1 kcal/mol to the
homodimer interface.
2.8. D2LR Oligomerization
HEK293T cells were co-transfected with 400 ng D2LR–SmBiT, D2LR–LgBiT, and increasing DNA
concentrations of native D2LR (0–600 ng) (Figure 5). Co-expression of native D2LR did not circumvent
or attenuate the complemented luminescent signal, but in fact it stimulated the D2LR oligomerization
(Figure 5A) in an expression-dependent manner. To rule out that crowding of GPCRs on the membrane
or nonspecific aggregation would result in trivial complementation of the NanoBiT proteins, the
muscarinic M1 receptor was co-transfected instead of the native D2LR (Figure 5B). Co-expression of the
M1 receptor did not modify the luminescent signal in a significant manner. Furthermore, also in the
presence of more D2LRs, spiperone still had an impact: upon treatment, the increase in oligomerization
by increasing amounts of native D2LR was less pronounced (Figure 5C). Specifically, when comparing
the experimental setup of HEK293T cells transiently expressing D2LR–LgBiT and D2LR–SmBiT with
the same setup but with high levels of co-transfected native D2LR (4:4:6) (Figure 5A), a significant
twenty-fold increase in luminescent signal was observed for the latter. On the other hand, when
treated with spiperone, only a five-fold difference between the same two experimental setups could be
observed (Figure 5C).
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3. Discussion
Over the past two decades, a growing body of evidence suggests that GPCRs are able to
form dimers and/or even higher-order oligomers [59]. Because these GPCRs are involved in many
physiological processes, these dimeric or oligomeric GPCR complexes are not only of paramount
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importance for possible alterations in signaling cascades, compared to their monomers, but also for
their association with debilitating diseases.
Interestingly, a significant increase of D2R dimerization has already been observed in post-mortem
striatal tissue of schizophrenia patients [48]. Concerning the dimer formation of D2Rs, as well as other
class A subfamily GPCRs [45,46], clear evidence for the transient characteristics of the dimer formation
has been provided by single-molecule tracking studies [31], with a lifetime of 68 ms being assigned to
the D2R dimer [28,42]. Although a lot of knowledge has been gathered concerning dimer formation of
the D2R, key questions still remain unanswered. For example, different D2R dimeric interfaces
have been proposed [29,33], as well as a hypothesis of multiple oligomerization interfaces [42].
Nevertheless, a recent interest has arisen in the establishment of a D2R TM5–TM6–TM5–TM6 dimeric
interface [32,40,41]. In our present study we have addressed the computational reliability of this
dimeric interface and its implication in the D2R homodimer by means of computational techniques
including microsecond-length MD simulations. In addition, targeting GPCR dimers with ligands or
selective chemical tools may elaborate the signaling behavior of dimers as well as their tendency or
preference towards GPCR–GPCR interactions. Nonetheless, this topic of ligand-induced modulation
of GPCR dimers has been much debated [60–62], with both arguing for and against. In the current
study, we further elaborate on this topic and demonstrate the ability of spiperone to alter the dynamic
equilibrium between D2LR monomers and dimers, with a clear preference towards monomers.
The Nanoluc® Binary Technology (NanoBiT®), developed by Promega in 2016 [63], proved to be
an interesting tool to study D2R dimers. In contrast to other complementation-based assays, NanoBiT®
offers the great advantage of being reversible, which gives opportunity to look into detail on the
kinetics of GPCR interactions. Importantly, since this system requires the fusion of LgBiT or SmBiT to
the GPCR of interest, the functionality of D2LR fusion proteins was demonstrated by mini-Gαi protein
recruitment to both receptors upon stimulation with the D2R agonist quinpirole.
Using this experimental HEK293T-based design, we screened six different D2R antagonists and
one agonist for their ability to modulate the level of D2LR dimer formation. This panel of ligands
compromises droperidol, spiperone, clozapine, olanzapine, risperidone, quinpirole, and haloperidol.
Although several of the aforementioned ligands have previously been classified as antagonists, one
should keep in mind that their inverse agonist capacity has now been recognized [64–67]. Of those,
the D2R antagonist/inverse agonist spiperone could significantly decrease the level of D2LR dimers
by 40%–60% in real-time and after long-term (up to 16 h) incubation. Another D2R antagonist,
haloperidol, also modulates the level of D2LR dimerization, but in a less significant manner (±30%).
In contrast, the D2R antagonist olanzapine significantly increases the level of D2LR dimer formation by
±45%. Furthermore, a class-dependent effect between the butyrophenones (haloperidol, spiperone,
and droperidol) and atypical antipsychotics (clozapine, risperidone, and olanzapine) could not be
distinguished. For the D2R agonist quinpirole, only a minor increase in luminescent signal provoked
by D2LR dimer formation could be observed. Although it was demonstrated that agonist addition
(i.e., dopamine and quinpirole) stabilized the formation of D2R dimers by a factor of 1.5 in a total
measure time of 400 ms by single-molecule tracking [28], we might conclude from this study that this
modulating effect does not significantly hold true for long-term effects. Nevertheless, one should keep
in mind that findings might differ due to diverse experimental assay setups as well.
In order to further examine the modulating capacity of spiperone on the D2LR dimer, we
performed screenings towards incubation time (real-time vs long-term effects), expression levels
of D2LR, and the specificity of the effect on the D2LR dimer. From this, we can conclude that a decrease
in the level of D2LR dimerization could readily be observed after approximately 30 min and was
still detected after long-term incubation up to 16 h. These data are in agreement with findings for
the dopamine D3R homodimer, for which similar effects were observed after 16 h treatment with
spiperone [68]. As a control, we examined whether spiperone altered expression levels of the D2LR,
which could cause a decrease in luminescent signal. This possibility was ruled out by both western
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blot analysis and the fluorescence analysis of a D2R–YFP fusion protein, expressed in cells that were or
were not treated with spiperone for 16 h.
Additionally, to ensure the specificity of the effect of spiperone on the D2R homodimer, the
same experimental set-up with another GPCR dimer was investigated. For this, we selected the
well-studied adenosine A2a receptor (A2a) and D2R dimer since many research groups have reported
on: (i) the formation of the dimer by several techniques such as BRET and FRET [20,69] and protein
complementation assays [70], (ii) specific dimer characteristics regarding signaling pathways of the
A2a–D2R dimer [71,72], (iii) the dimer interface [73], and (iv) allosteric mechanisms [54], among others.
Importantly, the fact that several studies have linked this dimer to Parkinson’s disease [74–77] lends
support to the relevance of research within this field. Nevertheless, to the best of our knowledge, the
modulating capacity of the D2R antagonist spiperone on the level of A2a–D2R dimer formation has
not been investigated yet. Overall, the effect of spiperone on the A2a–D2LR dimer was evaluated by
treatment with 10 µM spiperone for 16 h. However, this did not have a significant effect on the level of
A2a–D2LR dimer formation. Thus, since the spiperone-modulating capacity does not hold true for all
D2R dimer complexes, this effect might be specific for the D2LR homodimer or oligomer.
Computational techniques such as MD simulations have shown promise for studying GPCRs,
such as D2R, and their mechanisms of signaling transmission at the atomic level [30]. From a
computational point of view, in our study we observed noticeable differences between the orthosteric
binding poses of spiperone and clozapine in a D2R monomer, which select for different sidechain
conformations of Tyr1995.48 and Phe3906.52 on TM5 and TM6, respectively. Interestingly, the inward
conformations adopted by Tyr1995.48 and Phe3906.52 when spiperone is bound differ from the outward
conformations induced by clozapine, which are also favored in the modeled D2R homodimer. In this
study we have observed aromatic interactions between Tyr1995.48 and Phe3906.52, as well as occasional
H-bonding between Tyr1995.48, of both protomers in a model D2R homodimer, which could be
indicative of the relevance of these two residues in the establishment of a TM5–TM6–TM5–TM6
interface and their role in the homodimerization process. In addition, our D2R homodimer model with
a TM5–TM6–TM5–TM6 interface, in accordance with a previously published D2R–mGlu5 heterodimer
model presented by Qian et al. (2018) [40], is physically stable over microsecond-length MD simulations.
In addition to this homodimeric interface, it has been widely described that D2R heteromerizes through
a TM4–TM5–TM4–TM5 interface with other class A GPCRs, such as A2a and AT1 receptors [35–39].
Therefore, our results raise questions about the oligomerization interfaces D2R may form. In our present
study we observe that conformational changes specifically occurring in TM5 and TM6, resulting from
bound spiperone and involving inward Tyr1995.48 and Phe3906.52 sidechain conformations, may alter
the TM5–TM6–TM5–TM6 D2R homodimer interface. This fact may explain the results observed in
our experimental approach where spiperone specifically reduces levels of the D2R homodimer, while
having no significant effect on A2a–D2R heterodimer formation. Altogether, these results indicate
that the interfaces involved in homodimerization of D2R may differ from the interfaces involved
in heterodimerization processes with class A GPCRs, which could also differ between different
GPCR classes, in agreement with the hypothesis of multiple oligomerization interfaces presented by
Kaisai et al. (2014) [42].
Finally, D2LR oligomerization was investigated in a similar experimental design, using the
NanoBiT® assay. Although it was first postulated that co-transfection of the native D2LR would
attenuate the luminescent signal provoked by D2LR dimer formation by competing for interaction
with the D2LR–SmBiT and D2LR –LgBiT fusion proteins, the opposite was observed. Oligomerization
of the D2LR appeared to be concentration-dependent, with higher expression levels of native D2R
provoking complementation of the fusion proteins because of the close proximity to their corresponding
receptors, suggesting stimulation of the organization as higher-order oligomers. The fact that the
same outcome was not observed when co-expressing increasing amounts of the muscarinic M1
receptor confirms that this effect was not due to nonspecific aggregation or crowding of GPCRs.
The finding of an increased D2R homo-oligomerization with higher levels of expression is in agreement
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with literature [26,31,43,44,78] and has been reported for other dopamine receptors as well [68,79].
In addition, the effect of spiperone was evaluated on higher expression levels of D2LR as well. Also
here we demonstrated that spiperone reduces the level of D2LR–D2LR interactions. Rather than a
twenty-fold increase of luminescent signal resulting from higher D2LR expression levels, pre-treatment
with spiperone only resulted in a five-fold increase. To conclude, higher expression levels stimulate
D2LR–D2LR interaction, suggesting oligomerization. Also at these higher expression levels, spiperone
still exerts a negative impact on D2LR–D2LR interactions. Consistent with this concept, one might
speculate that spiperone could exert different pharmacological properties in different areas of the brain,
in co-relation with the expression level of D2LR.
Interestingly, Ng et al. (1996) [24] postulated that spiperone favors binding to the monomer over
the dimer, whereas risperidone binds to monomers as well as dimers. In light of our findings, one
might hypothesize that spiperone does not necessarily favor binding to the monomers, but simply
reduces the number of dimers, as observed in this study.
On the contrary, Armstrong et al. (2001) [25] reported quite opposite data obtained from ligand
binding experiments. These authors proposed a model wherein D2Rs can form dimeric units with two
orthosteric binding sites for two equivalents, which allows allosteric cooperativity. From experimental
data, it was suggested that the first and second equivalent of [3H]spiperone only exerted limited
cooperativity between the dimer units, in the absence or presence of sodium ions. On the other
hand, [3H]raclopride seems to prefer binding to monomeric units because of an observed negative
cooperative effect on the binding of the second equivalent upon binding of the first equivalent, which
results in a reduced affinity of the second site of the dimer for [3H]raclopride. Within the mindset of
this proposed model by Armstrong et al. [25], [3H]spiperone binds to the D2R dimer, and although no
negative effect on affinity of both binding sites due to cooperativity was observed by the authors, from
our data we can suggest that conformational changes within the dimer upon spiperone binding might
lead to dissociation of the dimer to its monomers.
Interestingly, a similar destabilizing effect of spiperone on D3R oligomeric complexes was reported
by Marsango et al. (2017) [68]. Using a spatial intensity distribution analysis (SpIDA) method, the
antipsychotics spiperone and haloperidol reduced the level of D3R dimerization in a ligand-dependent
manner. Moreover, this effect could be reversed upon ligand washout. Since the D3 and D2 receptors
are highly homologous and show a sequence identity of 78% [80], it might not be surprising that
certain ligands modulate these receptors in a similar way.
Although the development of the reversible complementation-based NanoBiT assay allows the
screening and discovery of ligands that could modulate the level of dimerization, this technique does
not provide information about the dynamics of the D2R dimers or oligomers at the single molecule
level. To allow visualization and tracking in real-time of the influence of spiperone on a D2R dimer
in the membrane of living cells, techniques such as single-molecule sensitive total internal reflection
fluorescence microscopy (TIRF-M) are recommended. Thus, based on the present understanding,
further research to study the effect of the D2R antagonist spiperone on the D2R homodimer in detail
is required.
4. Materials and Methods
4.1. Chemicals and Reagents
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with GlutaMAX, Opti-MEM® I
reduced serum medium and Gibco™ Penicillin-Streptomycin (10,000 U/mL), Hank’s balanced salt
solution (HBSS), Phusion high-fidelity (HF) PCR master mix with HF buffer, and T4 DNA ligase were
purchased from Thermo Fisher Scientific (Pittsburg, PA, USA). Fetal bovine serum (FBS) was purchased
from Biochrom, now part of Merck (Merck KGaA, Darmstadt Germany). Phosphate buffered saline
(PBS) was procured from Lonza (Lonza, Walkersville, MD, USA). Transient mammalian cell transfection
reagent polyethylenimine (PEI), poly-D-lysine, carbenicillin, Tween 20, and DMSO suitable for cell
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culture were purchased from Sigma-Aldrich (Steinheim, Germany). D2R antagonists spiperone,
clozapine, and haloperidol were purchased from Tocris Bioscience (Bio-techne, Abingdon, UK).
The Nano-Glo® Liv e Cell reagent and the GoTaq® DNA polymerase were from Promega (Madison,
WI, USA). Primers were synthesized by Eurofins Genomics (Ebersberg, Germany). Restriction enzymes
HindIII and EcoRI were from New England Biolabs (NEB, Massachusetts, US). E.Z.N.A.® MicroElute
Gel extraction kit, E.Z.N.A.® MicroElute Cycle-Pure kit and E.Z.N.A. plasmid DNA Mini/Midi kit
were from VWR International (Radnor, PA, USA). GelRed was purchased from Biotium (Fremont, CA,
USA). Luria Bertani broth and agar were procured from Lab M (Heywood, Bury, UK).
4.2. Cloning of the Dopamine D2R into the NanoBiT® plasmids
The human D2LR (NM_000795.3) was cloned into the NanoBiT® vectors (NB MCS1 and NB
MCS2), which were kindly provided by Promega (Madison, WI, USA). The NanoBiT® constructs
express a small subunit of the NanoLuciferase of 1 kDa (Small BiT, SmBiT) and a large subunit of
18 kDa (Large BiT, LgBiT). The D2LR was cloned into the NanoBiT® vectors prior to a 15 amino acid
encoding sequence, linking it to the SmBiT or LgBiT fragment, by performing a PCR reaction with
primers containing the specific restriction enzyme sites (Table 1). The PCR reaction was performed
with an MJ Research PTC-200 Thermal Cycler (GMI, Minnesota, USA), in a three-step manner: initial
denaturation (98 ◦C, 30 s), denaturation (98 ◦C, 10 s), annealing (Tm, 35 s), extension (72 ◦C, 42 s),
and final extension (72 ◦C, 5 min), for 30 cycles. PCR products were run on a 0.1% agarose gel and
purified with a MicroElute Gel extraction kit to remove parental DNA. After digestion with the specific
restriction enzymes for 3 h at 37 ◦C, the PCR product and the NanoBiT® vectors were purified with a
MicroElute Cycle-Pure kit and a MicroElute Gel extraction kit, respectively. Following ligation using T4
DNA ligase for 1 h at room temperature, the ligated product was transformed into a competent MC1061
Escherichia coli strain. After plating on carbenicillin-containing agar, resistant colonies were screened
for the presence of the insert by Colony PCR with Taq polymerase and subsequent restriction digest.
Coding sequences were verified by Sanger sequencing (Eurofins Genomics, Ebersberg, Germany).
As a control, the cDNA coding the human A2a receptor (A2a), a kind gift from F. Ciruela (Unitat
de Farmacologia, Barcelona, Spain), was fused to SmBiT and LgBiT in a similar way as for the D2LR
(Table 2). In addition, cannabinoid receptor 2 (CB2) fusion constructs, CB2–LgBiT and CB2–SmBiT,
were developed by performing a PCR reaction on the human CB2 coding sequence (as described
previously by our research group) [52].
Table 2. Primers for the development of the GPCR–NanoBiT fusion constructs. a: Forward (F)
and Reverse (R) primers (5′ > 3′) with restriction enzyme sites (bold), start codon (underlined) or
extra nucleotides ( marked in grey ) to ensure a correct reading frame. b: Annealing temperature. c:
Restriction enzyme.
Fusion Protein Primers (5′ > 3′) a Tm (◦C) b RE c
D2LR-LgBiT F GTTAAGCTTATGAAGACGATCATC 64
HindIII
R GCAGAATTC GC GCAGTGGAGGATC EcoRI
D2LR-SmBiT F GTTAAGCTTATGAAGACGATCATC 64
HindIII
R GCAGAATTC GC GCAGTGGAGGATC EcoRI
A2a-LgBiT F CGTTAAGCTTATGAAGACGATCATCGCCCTG 69
HindIII
R TGCAGAATTC GC AGAAACCCCAGCACC EcoRI
4.3. Cell Culture
4.3.1. Expression in HEK293T Cells
Human Embryonic Kidney 293T (HEK293T) (American Type Culture Collection (ATCC),
Manassas, Virginia, USA) cells were maintained in DMEM supplemented with 10% fetal bovine
serum (FBS), 100 µg/mL streptomycin, and 100 IU/L penicillin in a controlled environment (37 ◦C,
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98% humidity, 5% CO2). Prior to transfection, cells were cultured in 6-well plates at a density of
3× 105 cells/well in 2 mL DMEM + 10% FBS. To ensure low expression levels of GPCRs, only 200 ng of
each GPCR fused to a luminescent protein fragment was transiently transfected using PEI transfection
reagent in DMEM supplemented with 2% FBS. After 5 h of incubation with the transfection mixture,
the medium was refreshed with DMEM + 10% FBS.
4.3.2. Cell Preparation for Dimerization Assay with HEK293T Cells in Suspension
Forty-eight hours after transfection, cells were washed twice with PBS, scraped, and centrifuged
for 5 min at 1000× g. A bicinchoninic acid assay (BCA) was conducted on an aliquot of the transfected
cells in HBSS buffer, and all protein concentrations were measured. The cell suspensions were diluted
to bring them all to a density corresponding to a measured protein concentration of 600 ng/µL. For the
dimerization assay, the Nano-Glo Live Cell reagent, a non-lytic detection reagent containing furimazine
substrate, was 20× diluted using Nano-Glo Live Cell System (LCS) dilution buffer, and 25 µL was
added to each 96-well containing 100 µL cell suspension. End-point fluorescence or luminescence was
measured with the ClarioSTAR (BMG LABTECH) in a black and white 96-well plate, respectively.
4.3.3. Cell Preparation for Dimerization Assay with Adherent HEK293T Cells
Twelve hours after transfection, cells were reseeded in poly-D-lysine-pretreated white 96-well
plates at 0.5 × 105 cells/well. The next day, cells were washed twice with Opti-MEM® and 100 µL of
the reduced serum medium was added to each well. First, 25 µL of the Nano-Glo Live Cell reagent was
added, followed by an incubation of 15 min, monitored by the Tristar (as described previously [52]).
Afterwards, 10 µL of solvent control (blank sample, DMSO ≤ 0.1%) or ligand was added to obtain a
final concentration of 10 µM. The read-out was performed immediately upon treatment and monitored
for 1 h at room temperature by the TriStar2 LB 942 multimode microplate reader controlled by ICE
software (Berthold Technologies GmbH & Co., Bad Wildbad, Germany).
4.3.4. Fluorescence Normalization and Signal-To-Noise Ratio
To circumvent fluctuations in signal resulting from varying transfection efficiencies, a constant
amount of a plasmid encoding the fluorescent protein Venus (10% of total DNA transfected) was
co-transfected in all conditions. Luminescence data were normalized for the measured fluorescent signal.
As a negative control, the protein fragment SmBiT of the luminescence-based assays, not fused to
a receptor but to the HaloTag, was implemented. The luminescent/fluorescent signal obtained for this
condition (co-transfected with, e.g., D2LR–LgBiT) was considered as background and, consequently, a
signal-to-noise ratio could be derived.
4.4. NanoBiT®-Based Validation of the Functionality of D2LR Luminescent Fusion Proteins by mini-Gαi
Protein-Mediated Signaling
The plasmid encoding the mini-Gαi protein was kindly provided by the lab of Dr. A.
Chevigné (LIH Luxembourg Institute of Health, Luxembourg). The construct was PCR-amplified
using synthesized primers (Forward: 5′ ACTCAAGAATTCAATGATCGAGAAGCAGCTGCAG 3′
and Reverse: 5′ ACTCAAGAATTCTCAGAACAGGCCGCAGTCTCTC 3′) and subcloned into the
NanoBiT® constructs expressing LgBiT and SmBiT using EcoRI restriction sites flanked at both sites.
Sequences were verified by Sanger sequencing.
HEK293T cells were seeded in 6-well plates at a cell density of 5 × 105 cells/well. The next day,
cells were transiently transfected with 1.5 µg of each construct (D2LR–LgBiT and SmBiT–mini-Gαi or
D2LR–SmBiT and LgBiT–mini-Gαi) using FuGENE® HD transfection reagent (Promega) according to
the manufacturer’s instructions. For reseeding the cells in white 96-well plates, as well as monitoring
of the luminescent signal, the same procedure was followed as described in ‘Cell preparation for
dimerization assay with adherent HEK293T cells’. On the fourth day, cells were treated with quinpirole
(0.01 nM–10 µM) to evoke mini-Gαi protein recruitment to the D2LR.
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4.5. Detection of the Expression Levels of D2LR Dimers by Western Blot
Western blot analysis was executed as previously described [81], with some minor adaptations.
The day before transfection, HEK293T cells were seeded in 10-cm dishes at a density of
3 × 106 cells/well. PEI-mediated transient transfection was performed with plasmids encoding
D2LR–SmBiT and D2LR–LgBiT, each present at 2 µg per dish. The next day, cells were treated with
10 µM haloperidol, spiperone, clozapine, or solvent control for 16 h at 37 ◦C. On the fourth day, cells
were washed two times with PBS, harvested, and lysed using Polytron homogenizer for two 10 s
periods in ice-cold PBS buffer. Membrane pellets were obtained by centrifugation at maximum speed
for 25 min at 4 ◦C and dissolving in RIPA buffer (150 mM NaCl; 50 mM Tris HCl, pH 7.5; 1% NP-40;
0.5% deoxycholic acid; supplemented with fresh protease inhibitors: 5 µg/mL aprotinin, 0.4 mg/mL
pefabloc and 10 mM β-glycerol-phosphate disodium salt pentahydrate, and 10 µg/mL leupeptin).
The membrane pellets were rotated for 1 h at 4 ◦C, followed by a centrifugation for 20 min at maximum
speed. Next, the BCA method was performed on the supernatant to quantify the protein levels, with
bovine serum albumin dilutions as the standard. Cell lysates (50 µg) were heated in Laemmli buffer
supplemented with 10% β-mercaptoethanol and 5% bromophenol blue for 10 min at 37 ◦C. Proteins
were separated via a 10% SDS-PAGE for 1 h at 100V and transferred to a polyvinylidene difluoride
membrane. Membranes were blocked with blocking buffer (LI-COR Biosciences, Lincoln, NE, USA)
for 1 h at RT and incubated with rabbit anti-D2R antibody (RRID: AB_2571596) (Frontier Institute,
Hokkaido, Japan) overnight at 4 ◦C, followed by three washing steps with PBS + 0.05% Tween 20.
Afterwards, blots were incubated for 1 h in the dark with goat anti-rabbit IRDye680 LT (1/10,000)
(cat. no. 926–68021, LI-COR Biosciences, Lincoln, NE, USA) at RT. Equal loading of all conditions
was assessed by normalization by the levels of the constitutively expressed neuronal marker tubulin
with the monoclonal anti-α-tubulin antibody (cat. no. T5168, Sigma Aldrich, Steinheim, Germany).
After incubation with the primary antibody for 1 h, followed by three washing steps with PBS + 0.05%
Tween 20, blots were incubated for 1 h in the dark with the Alexa Fluor® goat anti-mouse secondary
antibody (cat. no. A-11001, Invitrogen, Carlsbad, CA, USA). Blots were visualized with the Odyssey®
Infrared Imaging system (IGDR, Rennes, France) and quantified by ImageJ software (NIH, Bethesda,
MD, USA).
4.6. Data Analysis
Concentration-response histograms were calculated after correction for the fluorescent signal
measured in the same well to compensate for transfection variability. Statistics were performed
using the non-parametric (Kruskal–Wallis) one-way ANOVA, followed by post hoc (Dunn’s multiple
comparison test) analysis to detect statistical differences amongst groups (p < 0.05) by the GraphPad
Prism software (San Diego, CA, USA).
Curve-fitting of concentration−response curves of the mini-Gαi coupling to the D2LR via a
nonlinear regression model (variable slope, four parameters) was employed to determine pEC50 values
(a measure of potency). The mean area under the curve (AUC) ± standard error of mean (SEM) was
calculated, with a total of 12 replicates for each data point.
4.7. Computational Modeling
A previously published D2R model [40], based on human D2R crystal structure (PDB id:
6CM4) [55], was generated using CHIMERA v1.11.2 [82] software (San Francisco, CA, USA) by
adding missing residues and converting the crystal mutated residues back to wild-type. In addition,
co-crystallized risperidone and endolysin fusion protein were removed from the D2R structure.
This D2R model was used as initial conformation for construction of three different molecular
systems: (i) spiperone-bound D2R monomer, (ii) clozapine-bound D2R monomer, and (iii) D2R
homodimer without bound antagonist. Coordinates for clozapine and spiperone were downloaded
from PubChem [83]. AUTODOCK v4.2 [84] software (La Jolla, CA, USA) was used to dock clozapine
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and spiperone into the monomeric D2R model. The selected docked conformation of each ligand
in the receptor represented the top hit identified by best predicted affinity in the largest docking
cluster. For construction of the D2R homodimer model, where two protomers of D2R interacted
via a symmetrical TM5–TM6–TM5–TM6 interface, two D2R monomers without bound antagonist
were initially superimposed onto respective protomers of the µ-opioid receptor homodimer crystal
structure (PDB id: 4DKL) [85]. The D2R homodimer model was then submitted to the ROSIE Web
server [58] for protein–protein docking using default parameters. The best docked homodimer
structure was identified by two factors: best interface score (“I_sc”) and best membrane-compatible
orientation. The D2R monomer, with bound spiperone or clozapine, and D2R homodimer without
bound antagonist complexes were energy minimized without restraints with CHIMERA [82] in the
AMBER-14SB force-field [86] to optimize protein–ligand or protein–protein interactions, respectively.
4.8. Molecular Dynamic (MD) Simulations
D2R monomer, with bound spiperone or clozapine, and D2R homodimer without bound antagonist
complexes were embedded separately into a 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC) membrane
and solvated with TIP3P water molecules using the CHARMM-GUI web-based interface [87]. Complexes
were oriented in the membrane according to the OPM database [88] entry of D2R crystal structure (PDB
id: 6CM4) [55] or µ-opioid receptor homodimer crystal structure (PDB id: 4DKL) [85] for monomer
and homodimer models, respectively. Charge-neutralizing ions (0.15 M KCl) were introduced into each
system. Parameters were automatically generated by CHARMM-GUI [87]. Membrane, water, and
protein parameters were generated according to the CHARMM36 force-field [89], whereas spiperone
and clozapine parameters were generated according to CGenFF v1.0.0 [90]. Molecular dynamics (MDs)
simulations of D2R monomer, with bound spiperone or clozapine, and D2R homodimer were performed
using the CHARMM36 force-field [89] with ACEMD [91] on specialized GPU-computer hardware
(Stanmore, Middlesex, UK). Each system was equilibrated for 28 ns at 300 K and 1 atm, with positional
harmonic restraints on protein heavy atoms progressively released over the first 8 ns of equilibration
and then continued without constraints. After equilibration, monomer and homodimer models were
subjected to unbiased continuous production runs under the same conditions for 3 µs.
4.9. MD Simulation Analysis
Analysis of MD simulations of D2R monomer, with bound spiperone or clozapine, and D2R
homodimer without bound antagonist were performed using VMD software v1.9.2 [92] (Chicago,
IL, USA). In detail, root mean square deviation (RMSD) measurements of the backbone of the
transmembrane domain (TMD) of D2R was performed to observe receptor conformational change with
respect to the initial D2R monomeric crystal structure (PDB id: 6CM4) [55] or initial D2R homodimer
model. Likewise, RMSD measurements of either clozapine or spiperone in their respective MD
simulations were used to monitor ligand stability in the orthosteric pocket of the D2R monomer.
Residues in close contact (protein-ligand distance <3.5 Å) with co-crystallized ligand risperidone
were compared, in terms of RMSD with MD conformations of D2R monomer with bound stable
clozapine or spiperone, to observe differences between induced-fit of both ligands. Similarly, residues
frequently close-contacted by either clozapine or spiperone in respective MD simulations, within
simulation time-periods where ligands remain stable, were identified with a TCL script executed
in VMD [92], thus defining ligand-specific D2R orthosteric pockets. After visual comparisons of
the D2R monomer, with bound spiperone or clozapine, and D2R homodimer conformations, we
performed an analysis of Tyr1995.48 and Phe3906.52 χ1 dihedral angle conformations using an in-house
custom TCL script executed in VMD [92]. An arbitrary threshold of 240◦ was selected to classify
Tyr1995.48 and Phe3906.52 χ1 dihedral angle cis or trans-conformation (> or <240◦, respectively).
The proportion of each conformation was measured. Distance analyses of the interface of D2R
homodimer were performed using the TCL script executed in VMD [92]. An energetic analysis of the
D2R homodimer TM5–TM6–TM5–TM6 interface was performed with FoldX v.4 (Barcelona, Catalonia,
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Spain) [93]. Alanine scanning of D2R homodimer Tyr1995.48 and Phe3906.52, generating Y199A and
F390A mutations, followed by energetical analysis with FoldX v.4 [93], was carried out to measure the
contribution of these residues in the homodimer interface.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/7/
1686/s1.
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